Michael Hanson Joins ActivBiotics Board

LEXINGTON, Mass., Dec. 6 /PRNewswire/ -- ActivBiotics, Inc., a privately held biopharmaceutical company, today announced the election of Michael E. Hanson as a new director.

Michael E. Hanson is a Founding Partner of Barnard Life Sciences, LLC, a venture capital and health care consulting firm, and is currently a director of Indevus Pharmaceuticals, Inc., and Glycogenesys, Inc. He served as a director of MGI Pharma, Inc., an oncology-focused biopharmaceutical company, from May 1998 through May 2001. From 1973 to 1997, Mr. Hanson, served in a variety of management positions in sales, marketing and new product development at Eli Lilly and Company. At the time of his retirement from Eli Lilly, he was President of the Internal Medicine Business Unit, which included cardiovascular and oncology products, and was a member of the Operations Committee. While at Eli Lilly, he was Director of New Product Planning and Licensing; Executive Director of Japan Business Planning; President and General Manager of Eli Lilly Japan KK; and Vice President of Lilly Research Laboratories. Mr. Hanson holds a B.S. in Pharmacy from North Dakota State University, an M.S. in Hospital Pharmacy Administration from the University of Minnesota and is a graduate of the Advanced Management Program from Harvard Business School.

"Michael Hanson brings a wealth of commercialization and marketing experience to the ActivBiotics' board," said Ray Baddour, Chairman of ActivBiotics. "As we advance our Phase 3 program in peripheral arterial disease, we expect Mike to contribute greatly to our commercialization efforts."

About ActivBiotics

ActivBiotics, Inc. is a private biopharmaceutical company located in Lexington, MA, focused on the discovery, development and commercialization of breakthrough antibacterials for high-value chronic and infectious disease markets. The Company's lead product candidate, rifalazil, is being studied in a pivotal study in patients with intermittent claudication, a manifestation of lower extremity arterial disease. The Company's lead pre-clinical compound in its pipeline of novel rifamycins, ABI-0043, shows significant potential for the treatment of infections caused by Gram-positive pathogens, including Staphylococcus aureus and MRSA (methicillin-resistant Staphylococcus aureus). For more information, please visit http://www.activbiotics.com.

ActivBiotics, Inc.

CONTACT: Jim Warren, CFO of ActivBiotics, Inc., +1-781-372-4814,jwarren@activbiotics.com

Back to news